RAS mutations sit near the center of cancer biology. They are among the most common genetic drivers of tumors, yet for decades the proteins they produce were considered exceptionally difficult drug targets. A new early-stage study of daraxonrasib suggests that broader inhibition across RAS variants may be possible in lung cancer, although the toxicity profile makes clear how early the work remains.
The phase 1 study enrolled patients with previously treated, metastatic RAS-mutant non-small-cell lung cancer. Across active dose ranges, objective tumor responses were seen in roughly one-third of patients. Response rates varied by dose, rising from about 31% in lower-dose groups to the mid-30% range at higher exposures. For a population whose cancers had already progressed through prior treatment, that degree of tumor shrinkage is clinically meaningful enough to justify further study.
Daraxonrasib is designed as a pan-RAS inhibitor rather than a drug limited to one mutation such as KRAS G12C. That distinction matters because RAS-driven cancers are genetically diverse. The success of mutation-specific inhibitors proved that RAS was not truly undruggable, but it also exposed a new challenge: each narrow drug covers only a subset of patients, and tumors can escape by activating other RAS states or pathways. A broader inhibitor could potentially reach more cancers and make resistance harder, but broader biological reach can also mean broader toxicity.
That trade-off is visible in the trial. Grade 3 or higher adverse events occurred in more than half of participants in the reported safety population. Early oncology trials often include very sick patients and are designed to identify the highest tolerable dose, so toxicity is expected. Still, the rate means the headline response number cannot be separated from the question of how much treatment patients can safely receive and for how long.
The next questions are therefore practical as well as molecular. Researchers need to define the dose that gives durable tumor control without unacceptable side effects, determine whether particular RAS mutations respond better than others and measure how long responses last. Combination strategies may also matter, but adding drugs can compound toxicity.
Daraxonrasib does not close the RAS story. It extends it. The field has moved from the belief that RAS could not be targeted to a growing set of ways to interfere with its signaling. A pan-RAS strategy could expand that reach considerably if later trials confirm durable benefit. The current result is a promising signal from an early study, not yet evidence that the drug should become standard treatment for RAS-mutant lung cancer.